In the phase III ExteNET trial, neratinib improved the 2-year disease-free survival (DFS) rate among patients with early-stage HER2-positive breast cancer who had already completed adjuvant trastuzumab-based therapy up to 1 year before joining the study. Christy A. Russell, MD The 2-year DFS...
Patient-detected breast cancer is not well described, and its association with survival is not known. Initial breast cancer detection methods were extracted from patient chart notes in a registry cohort of women aged 40-93 with primary invasive breast cancer seen at the community-based regional can...
The 5-year survival rate for breast cancer among Korean women has increased steadily; however, breast cancer remains the leading cause of cancer mortality among women. One-carbon metabolism, which requires an adequate supply of methyl group donors and B vitamins, may affect the prognosis of breast...
Abbas et al (2022) noted that with the incidence of breast cancer, breast cancer survival rates, and prophylactic mastectomies all increasing, efforts to optimize breast reconstruction and improve QOL are becoming increasingly important. Nerve coaptation has been examined for its potential to remedy t...
According to the Male Breast Cancer Coalition, government health reports show an estimated 2550 new cases in US with a mortality rate between 280-480. This indicates that over the past 10 years, new cases are up by 22% and mortality rate is up by about 19% from previous years. Advocates...
Molecular profiling of circulating extracellular vesicles (EVs) provides a promising noninvasive means to diagnose, monitor, and predict the course of metastatic breast cancer (MBC). However, the analysis of EV protein markers has been confounded by the
Molecular profiling guides precision treatment of breast cancer; however, Asian patients are underrepresented in publicly available large-scale studies. We established a comprehensive multiomics cohort of 773 Chinese patients with breast cancer and systematically analyzed their genomic, transcriptomic, proteomic...
since the diagnosis of invasive breast carcinoma) and disease-free survival (number of consecutive years the patient was alive without breast cancer or other cancer relapse related to the breast carcinoma since the date of diagnosis) were calculated from the information gathered in the chart review....
musculocutaneous flap (TRAM), were compared to the patients who underwent CM in terms of breast-cancer specific survival (BCSS) rate, distant metastasis-free survival (DMFS) rate, and local recurrence (LR) rate.During the study period, 6028 patients underwent mastectomy for breast cancer. Of...
Statins, commonly used to treat hypercholesterolemia, have also been proposed as anti-cancer agents. The identification of a predictive marker is essential. The 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR), which is inhibited by statins, might